Biological patent thickets and delayed access to biosimilars, an American problem
{{output}}
Our study seeks to determine whether patent thickets covering biologic drugs are responsible for delayed biosimilar market entry. We compare patent assertions against the same biosimilar drugs across three countries. On average nine to twelve times more patent... ...
